Fourteen studies comprising 2883 patients reported the POAF prevalence in patients pretreated with a statin or placebo25-38 . Statin was correlated to a reduced prevalence of POAF (312/1456 [21.4%] versus 393/1427 [27.5%]). We encountered a statistically significant difference between the two considered groups (OR 0.71; 95% CI: 0.60 to 0.85, p-value = 0.0001). There was severe heterogeneity observed between the 14 studies (I2= 69%) (Figure 4 ). However, If we only consider studies with ≥ 199 patients, the results are divergent (OR 0.89; 95% CI: 0.74 to 1.09, p-value = 0.26 ; I2= 74%) (Figure 5 ).